Jorgensen C, Djouad F, Apparailly F, Noël D
Service d'Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France.
Gene Ther. 2003 May;10(10):928-31. doi: 10.1038/sj.gt.3302019.
Allogeneic hematopoietic stem cell transplantation, after sublethal irradiation of recipient animals, is capable of inducing donor-specific tolerance facilitating subsequent organ transplantation. This approach could reintroduce tolerance in autoimmune diseases and it has been applied to treat autoimmune diseases with, however, a great susceptibility of recurrence. Mesenchymal stem cells (MSCs) present within the bone marrow could be critical to the immunosuppressive effect of the treatment. This tolerance induction may be useful in allogeneic transplantations, where low incidence of graft-versus-host disease was observed when the hematopoietic graft was coinjected with MSCs. In this paper, we discuss the use of MSCs in different therapeutic strategies either as immunosuppressive agents or genetically engineered to express molecules acting against the autoimmune process.
在对受体动物进行亚致死剂量照射后，同种异体造血干细胞移植能够诱导供体特异性耐受，从而促进后续的器官移植。这种方法可以在自身免疫性疾病中重新诱导产生耐受，并且已经被应用于治疗自身免疫性疾病，然而，其复发的易感性很高。骨髓中存在的间充质干细胞（MSCs）可能对该治疗的免疫抑制作用至关重要。这种耐受诱导在同种异体移植中可能是有用的，当造血移植物与MSCs共同注射时，观察到移植物抗宿主病的发生率较低。在本文中，我们讨论了MSCs在不同治疗策略中的应用，它们既可以作为免疫抑制剂，也可以经过基因工程改造来表达对抗自身免疫过程的分子。
